BMS-986242（Cat No.:I023560）is a fully human, monoclonal antibody that targets CD40, a costimulatory protein found on antigen-presenting cells critical for immune activation. By modulating CD40 signaling, BMS-986242 enhances T-cell priming and promotes robust immune responses against tumors. Unlike agonistic CD40 antibodies that risk systemic toxicity, BMS-986242 is designed to achieve a balanced immunostimulatory effect with improved safety. It is under investigation in combination with checkpoint inhibitors and other immunotherapies for treating various solid tumors. BMS-986242 supports research into immune-oncology strategies aimed at enhancing antitumor immunity via CD40 pathway modulation.